An Interview With NeuroBo’s CEO To Discuss The Company’s GLP-1 Dual Agonist

NeuroBo Pharmaceuticals is a clinical stage drug development company with a focus on weight loss and a GLP-1 Dual Agonist.

Its most advanced drug candidate, A-1726, is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity. The IND approval is expected soon with Phase 1 trials commencing shortly thereafter. Its other therapy is DA-124, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Its Phase 2a first patient was dosed September 15, 2023 with interim data due in 1H 2024. Full results due in 2H 2024. The company is backed by strategic partner and major shareholder, Dong-A ST. DA-1726 outperformed Semaglutide (WEGOVY), a GLP-1 agonist, in mouse models of obesity. The company has a negative EV.

The ideas presented on this site do not constitute a recommendation to buy or sell any security. Investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action. You should be aware of the risks involved in stock investing, and you use the material contained herein at your own risk. Neither SYNTHETIC.COM nor any of its contributors are responsible for any errors or omissions which may have occurred. The analysis, ratings, and/or recommendations made on this site do not provide, imply, or otherwise constitute a guarantee of performance. SYNTHETIC.COM posts may contain financial reports and economic analysis that embody a unique view of trends and opportunities. Accuracy and completeness cannot be guaranteed. Investors should be aware of the risks involved in stock investments and the possibility of financial loss. It should not be assumed that future results will be profitable or will equal past performance, real, indicated or implied. The material on this website is provided for information purpose only. SYNTHETIC.COM does not accept liability for your use of the website. The website is provided on an “as is” and “as available” basis, without any representations, recommendations, warranties or conditions of any kind.

An Interview With NeuroBo’s CEO To Discuss The Company’s GLP-1 Dual Agonist was last modified: February 1st, 2024 by Simons Chase